13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,380 - (DrugBank : 407) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05284175
(ClinicalTrials.gov)
April 20229/3/2022A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderA Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderNeuromyelitis Optica Spectrum DisorderDrug: OrelabrutinibPeking Union Medical College HospitalBeijing InnoCare Pharma Tech Co., Ltd.;GCP ClinPlus Co., Ltd.Not yet recruiting18 Years75 YearsAll23N/AChina
2NCT04711148
(ClinicalTrials.gov)
March 1, 20218/1/2021A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisA Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological ActivityRelapsing Remitting Multiple SclerosisOther: placebo;Drug: orelabrutinibBeijing InnoCare Pharma Tech Co., Ltd.NULLRecruiting18 Years55 YearsAll160Phase 2United States;China;Poland;Ukraine